Bronchiectasis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Bronchiectasis pipeline constitutes 15+ key companies continuously working towards developing 15+ Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Bronchiectasis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bronchiectasis Market.

The Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Bronchiectasis Pipeline Report: https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Bronchiectasis treatment therapies with a considerable amount of success over the years.
• Bronchiectasis companies working in the treatment market are SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Bronchiectasis treatment
• Emerging Bronchiectasis therapies in the different phases of clinical trials are- S1226, Brensocatib, P339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Bronchiectasis market in the coming years.
• In November 2025, Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on patient-centric innovation, announced that the European Commission has approved BRINSUPRI (brensocatib 25 mg tablets) for treating non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older who have experienced two or more exacerbations within the previous 12 months. BRINSUPRI is a first-in-class therapy and represents the first and only approved treatment specifically indicated for NCFB in the European Union. The medication underwent accelerated assessment by the European Medicines Agency (EMA), reflecting its significant public health importance.
• In August 2025, The FDA has approved brensocatib (Brinsupri; Insmed) for the treatment of non-cystic fibrosis bronchiectasis, marking it as the first approved therapy for this patient group and the first dipeptidyl peptidase 1 (DPP1) inhibitor authorized for a neutrophil-driven disease. Brensocatib is an oral, small-molecule, reversible DPP1 inhibitor that blocks DPP1, reducing the activation of neutrophil serine proteases, which play a central role in inflammation and tissue damage in chronic lung diseases such as bronchiectasis.
• In February 2025, The FDA assigned priority review to brensocatib, an investigational therapy for patients with non-cystic fibrosis bronchiectasis. After the new drug application was accepted, the target action date was scheduled for August 12, 2025. If approved, brensocatib would be the first approved treatment for bronchiectasis and the inaugural drug in the dipeptidyl peptidase 1 class for neutrophil-driven diseases.
• In February 2025, Verona Pharma is a biopharmaceutical company focused on creating and commercializing innovative therapies for chronic respiratory diseases with significant unmet needs. Its first commercial product, OhtuvayreTM (ensifentrine), is the first inhaled maintenance therapy for COPD that uniquely combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ensifentrine also holds promise for treating non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory disorders.

Bronchiectasis Overview
Bronchiectasis is a chronic lung condition characterized by permanent widening and damage of the airways (bronchi), leading to mucus buildup, frequent lung infections, coughing, and difficulty breathing. It often results from infections, genetic disorders like cystic fibrosis, or conditions that impair the lungs' ability to clear mucus. Early management can help reduce complications and improve quality of life.

Get a Free Sample PDF Report to know more about Bronchiectasis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/bronchiectasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Bronchiectasis Drugs Under Different Phases of Clinical Development Include:
• S1226: SolAeroMed
• Brensocatib: Insmed
• NP339: NovaBiotics Ltd
• Research Programme:NCFB: Synspira Therapeutics
• Research programme: mucolytic agents: Parion Sciences
• CHF 6333: Chiesi Farmaceutic
• CSL787: CSL Behring
• HSK31858: Haisco Pharmaceutical
• S-1226: SolAeroMed Inc.
• Benralizumab: AstraZeneca
• Colistimethate sodium: Zambon SpA
• BI 1291583: Boehringer Ingelheim
• AP-PA02: Armata Pharmaceuticals
• ARINA-1: Renovion

Bronchiectasis Route of Administration
Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Bronchiectasis Molecule Type
Bronchiectasis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Bronchiectasis Pipeline Therapeutics Assessment
• Bronchiectasis Assessment by Product Type
• Bronchiectasis By Stage and Product Type
• Bronchiectasis Assessment by Route of Administration
• Bronchiectasis By Stage and Route of Administration
• Bronchiectasis Assessment by Molecule Type
• Bronchiectasis by Stage and Molecule Type

DelveInsight's Bronchiectasis Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Bronchiectasis product details are provided in the report. Download the Bronchiectasis pipeline report to learn more about the emerging Bronchiectasis therapies
https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Bronchiectasis Therapeutics Market include:
Key companies developing therapies for Bronchiectasis are - Zambon, Boehringer Ingelheim, SolAeroMed, Insmed Incorporated, Chiesi Farmaceutici, Renovion, Haisco Pharmaceutical, Armata Pharmaceuticals, AstraZeneca, CSL Behring, and others.

Bronchiectasis Pipeline Analysis:
The Bronchiectasis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Bronchiectasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis Treatment.
• Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchiectasis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Bronchiectasis drugs and therapies
https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bronchiectasis Pipeline Market Drivers
• Increasing prevalence of bronchiectasis worldwide, particularly among aging populations
• Rising awareness and improved diagnosis of the disease
• Advancements in novel therapies targeting underlying causes and inflammation
• Growing investment in research and development by pharmaceutical companies
• Expansion of clinical trials exploring innovative drug candidates

Bronchiectasis Pipeline Market Barriers
• High costs associated with drug development and clinical trials
• Complexity of the disease with heterogeneous patient populations
• Limited efficacy of some current therapeutic options in advanced cases
• Stringent regulatory requirements for approval of new treatments
• Challenges in patient recruitment for clinical trials

Scope of Bronchiectasis Pipeline Drug Insight
• Coverage: Global
• Key Bronchiectasis Companies: SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others
• Key Bronchiectasis Therapies: S1226, Brensocatib, P339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others
• Bronchiectasis Therapeutic Assessment: Bronchiectasis current marketed and Bronchiectasis emerging therapies
• Bronchiectasis Market Dynamics: Bronchiectasis market drivers and Bronchiectasis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.